Shares of Bio-Techne Corp. rallied 5.67% to $63.03 Monday, on what proved to be an all-around favorable trading session for ...
Bio-Techne (TECH) is back in focus after a recent analyst downgrade that cited softer organic growth and a weaker free cash ...
Barchart on MSN
Here's what to expect from Bio-Techne's next earnings report
Bio-Techne Corporation (TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and sells life science ...
Valued at a market cap of $9.3 billion, Bio-Techne Corporation (TECH) is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities.
Bio-Techne TECH reported third-quarter fiscal 2025 adjusted earnings per share (EPS) of 56 cents, which surpassed the Zacks Consensus Estimate by 9.8%. The bottom line improved from the year-ago ...
Shares of Bio-Techne (NASDAQ:TECH) traded sharply lower in the early premarket trading on Wednesday after KeyBanc Capital Markets downgraded the stock, arguing that the life sciences firm is ...
RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...
Shares of Bio-Techne Corporation (NASDAQ:TECH) traded higher after the life sciences company topped analysts' expectations with its Q2 FY25 results, indicating a faster topline growth amid early signs ...
Bio-Techne (NASDAQ:TECH – Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, October 30th. Analysts expect the company to announce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback